Related Experiment Video
Updated: May 29, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using
D M Rommelfanger1, C P Offord, J Dev
1Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
Tumor selective, replication competent viruses are being tested for cancer gene therapy. This approach introduces a new therapeutic paradigm due to potential replication of the therapeutic agent and induction of a tumor-specific immune response. However, the experimental outcomes are quite variable, even when studies utilize highly inbred strains of mice and the same cell line and virus. Recognizing that virotherapy is an exercise in population dynamics, we utilize mathematical modeling to understand the variable outcomes observed when B16ova malignant melanoma tumors are treated with vesicular stomatitis virus in syngeneic, fully immunocompetent mice. We show how variability in the initial tumor size and the actual amount of virus delivered to the tumor have critical roles on the outcome of therapy. Virotherapy works best when tumors are small, and a robust innate immune response can lead to superior tumor control. Strategies that reduce tumor burden without suppressing the immune response and methods that maximize the amount of virus delivered to the tumor should optimize tumor control in this model system.
Insights
Mathematical modeling reveals that early-stage tumors and effective virus delivery enhance cancer virotherapy outcomes. Optimizing these factors is key for successful tumor treatment using replication-competent viruses.
Area of Science:
- Oncolytic Virotherapy
- Mathematical Biology
- Immunotherapy
Background:
- Replication-competent viruses offer a novel cancer gene therapy approach by replicating within tumors and stimulating immune responses.
- Virotherapy outcomes are highly variable, even under controlled experimental conditions.
Purpose of the Study:
- To utilize mathematical modeling to understand variability in oncolytic virotherapy outcomes.
- To identify critical factors influencing the efficacy of vesicular stomatitis virus treatment in B16ova melanoma models.
Main Methods:
- Mathematical modeling of population dynamics applied to virotherapy.
- Analysis of vesicular stomatitis virus treatment in syngeneic B16ova melanoma mouse models.
Main Results:
- Initial tumor size significantly impacts therapeutic success; smaller tumors respond better.
- The quantity of virus delivered to the tumor is a critical determinant of treatment outcome.
- A strong innate immune response correlates with superior tumor control.
Conclusions:
- Virotherapy is most effective against small tumors with robust innate immunity.
- Strategies enhancing virus delivery and reducing tumor burden without compromising immunity are crucial for optimizing virotherapy.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...